Home » Newsletters » BioWorld Science

BioWorld Science

April 28, 1999

View Archived Issues

Transkaryotic Therapies: Q1 1999 highlights

Connetics: Q1 1999 highlights

Allelix: Q2 1999 highlights

LXR Biotechnology receives disappointing preliminary preclinical results with Elirex

Micro Therapeutics begins brain tumor trial for Embolyx

Sheffield's metered-dose inhaler in clinical trials in Europe

Medtronic's urinary control device approved by FDA

Scotia: Annual Report 1998

Kissei designs new series with potent and selective bronchodilating effects

Inhibitors of NOS described by Pfizer

Novel quinolones with antitumor/antibacterial effects synthesized in China

Chinese investigators develop new antimicrobial agents

Sepracor's (R,R)-formoterol demonstrates fast-onset, long-lasting effects on FEV1 in phase IIa study

Design and evaluation of prodrugs of MAO-A inhibitors presented by Astra Arcus

Spotlight on IL-5 as a target for the treatment of inflammatory diseases

Preliminary evidence of efficacy and safety of N-acetylcysteine in AD

Improvement in spasticity noted with small doses of Zanaflex

SciClone awarded Cystic Fibrosis Foundation grant for CPX

Lamotrigine effective in HIV-associated painful sensory polyneuropathy

Harvard Scientific considers changing name

U.S. patent issued to NitroMed, providing protection for MED/FSAD treatment program

Canadian launch for world's first Lyme disease vaccine

Tryptamine analogues as potent and selective human 5-HT2A antagonists

Safety and immunogenicity of TA-GW demonstrated in phase IIa study

Guilford's new PARP inhibitors potentially useful for wide variety of disorders

Japanese marketing approval granted for AIDS wasting treatment

Safety and efficacy of riluzole examined in pilot study in early, untreated PD

First E.U. approval of Atridox for periodontal disease

SunPharm: year-end 1998 highlights

NDA for Natrecor not approved by FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...